Marcos R Gonzalez, Erhan Okay, Joseph O Werenski, Joseph J Connolly, Andrew Pfeiffer, Erik T Newman, Kevin A Raskin, Santiago A Lozano-Calderón
{"title":"What Are the Long-Term Clinical and Functional Outcomes After Hemicortical Allograft Reconstruction for Primary Bone Tumors?","authors":"Marcos R Gonzalez, Erhan Okay, Joseph O Werenski, Joseph J Connolly, Andrew Pfeiffer, Erik T Newman, Kevin A Raskin, Santiago A Lozano-Calderón","doi":"10.1002/jso.28147","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hemicortical allograft reconstruction is associated with low short-term complication rates and excellent functional outcomes. However, data on their long-term complication profile and patient-reported outcomes is scarce to non-existent.</p><p><strong>Methods: </strong>Patients with hemicortical resection and allograft reconstruction for primary bone tumors were included. The Henderson classification for biologic reconstruction was used to classify allograft failures. Functional outcomes at a minimum of 10 years postoperatively were assessed.</p><p><strong>Results: </strong>Twenty-four patients with femur hemicortical allograft and 20 with tibia allograft were included. Allograft failure and reoperation occurred in 39% and 52% of patients, respectively. The main causes of allograft failure were infection, soft-tissue failure, and structural failure (9% each). Tibia allografts had a higher rate of failure due to infection (p = 0.02) and nonunion (p = 0.049) compared to femur allografts. There were no differences in allograft failure-free survival based on bone (tibia vs. femur) and osteosynthesis type (plate vs. screw and plates). Median TESS-LE and LEFS scores were 98.8% and 87.5% for tibia allografts, and 98.1% and 97.5% for femur allografts, respectively.</p><p><strong>Conclusion: </strong>Long-term allograft failure-free survival was excellent, with infection and soft-tissue failures as the main failure mechanisms. At last follow-up, patients who still had the hemicortical allograft displayed excellent functional outcomes.</p><p><strong>Level of evidence: </strong>Level IV.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.28147","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hemicortical allograft reconstruction is associated with low short-term complication rates and excellent functional outcomes. However, data on their long-term complication profile and patient-reported outcomes is scarce to non-existent.
Methods: Patients with hemicortical resection and allograft reconstruction for primary bone tumors were included. The Henderson classification for biologic reconstruction was used to classify allograft failures. Functional outcomes at a minimum of 10 years postoperatively were assessed.
Results: Twenty-four patients with femur hemicortical allograft and 20 with tibia allograft were included. Allograft failure and reoperation occurred in 39% and 52% of patients, respectively. The main causes of allograft failure were infection, soft-tissue failure, and structural failure (9% each). Tibia allografts had a higher rate of failure due to infection (p = 0.02) and nonunion (p = 0.049) compared to femur allografts. There were no differences in allograft failure-free survival based on bone (tibia vs. femur) and osteosynthesis type (plate vs. screw and plates). Median TESS-LE and LEFS scores were 98.8% and 87.5% for tibia allografts, and 98.1% and 97.5% for femur allografts, respectively.
Conclusion: Long-term allograft failure-free survival was excellent, with infection and soft-tissue failures as the main failure mechanisms. At last follow-up, patients who still had the hemicortical allograft displayed excellent functional outcomes.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.